A study that identifies new heart attack risk factors and supports the use of a blood test for detection in patients will be published in the AACE (American Association of Clinical Endocrinologists) Journal.

 

As many as 500,000 people in the United States have a heritable and potentially fatal heart disease called hypertrophic cardiomyopathy.

InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114 patients were presented at a major cardiology congress in Israel in December. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next-generation MGuard drug eluting stent (DES) platform. The company also announced ipsilateral diffusion weighted magnetic resonance imaging (DW-MRI) results from the CARENET Trial for the CGuard system which successfully completed enrollment in July.

Sorin Group announced U.S. Food and Drug Administration (FDA) clearance for Memo 3-D ReChord, a semi-rigid annuloplasty ring for mitral valve repair.

The issue of sudden cardiac death has long been a concern of heart specialists, for cardiac arrest often hits young, apparently healthy and athletic people out of the blue.

Vena Cava Filters, Embolic protection, Pulmonary Embolism, Venous Therapies

The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States is set to enroll the first patient in spring 2015 with participation from seven filter manufacturers.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now